


## **Supplemental Information**


### **Hepatic JAK2 protects against atherosclerosis through circulating IGF-1**

Tharini Sivasubramaniyam, Stephanie A. Schroer, Angela Li, Cynthia T. Luk, Sally Yu Shi, Rickvinder Besla, David W. Dodington, Adam H. Metherel, Alex P. Kitson, Jara J. Brunt, Joshua Lopes, Kay-Uwe Wagner, Richard P. Bazinet, Michelle P. Bendeck, Clinton S. Robbins, and Minna Woo




**Supplemental Figure 1. *L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>* mice develop more atherosclerosis on chow diet.**

*L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>* and *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>* littermate controls were fed a standard rodent chow diet for 22 weeks. **(A)** Representative photographs of *en face* Oil-red-O (ORO) staining and quantification of atherosclerotic plaque area in descending aortas of 22-week-old *L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>* mice (n=3) and control *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>* mice (n=3). Scale bar: 1 cm. Each dot in the scatter plot indicates an individual animal. **(B)** Representative images of longitudinal sections from the aortic arch of 22-week-old *L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>* mice and control *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>* mice stained with H&E. B: brachiocephalic artery; C: left common carotid; S: subclavian artery; L: lesser curvature. Scale bar: 200  $\mu$ m. Data represent mean  $\pm$  SEM. Differences between groups were analyzed for statistical significance by Student unpaired t-test. \*P < 0.05.




**Supplemental Figure 2. Expression of *Jak2* and *Igf1* mRNA expression in the aortic arch of *L-Jak2<sup>-/-</sup>Ldlr<sup>-/-</sup>* mice.** *L-Jak2<sup>-/-</sup>Ldlr<sup>-/-</sup>* and *L-Jak2<sup>+/+</sup>Ldlr<sup>-/-</sup>* littermate controls were fed an atherogenic diet containing 1.25% cholesterol for 12 weeks, starting at 6 weeks of age. (A and B) Quantitative real time PCR (qRT-PCR) analysis of *Jak2* and *Igf1* mRNA expression in aortic arches from *L-Jak2<sup>-/-</sup>Ldlr<sup>-/-</sup>* mice (n=4-5) and control *L-Jak2<sup>+/+</sup>Ldlr<sup>-/-</sup>* mice (n=5-6). Values are normalized to 18S mRNA levels and presented as fold change over control group. Each dot in the scatter plot indicates an individual animal. Data represent mean ± SEM. Differences between groups were analyzed for statistical significance by Student unpaired t-test.



**Supplemental Figure 3. IGF-1 infusion attenuates hepatic steatosis but does not affect glucose tolerance, insulin sensitivity and total serum cholesterol or triglyceride levels in *L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>* mice.** Vehicle (saline + 10 mmol/L HCl) or human Long R3 IGF-1 (1.0 mg/kg/day), a biologically active IGF-1 analog, was administered by subcutaneous osmotic pumps into 8-week-old *L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>* mice and *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>* littermate controls for 12 weeks while on an atherogenic diet containing 0.2% cholesterol. (A) Glucose tolerance test in overnight fasted vehicle-infused *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>* (n=6), IGF-1-infused *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>* (n=4),

vehicle-infused  $L-Jak2^{-/-}ApoE^{-/-}$  (n=8) and IGF-1-infused  $L-Jak2^{-/-}ApoE^{-/-}$  (n=5) mice. Mice received glucose (1 g/kg) intraperitoneally and blood glucose was measured sequentially for 120 minutes. **(B)** Insulin tolerance test in 4 hour fasted vehicle-infused  $L-Jak2^{+/+}ApoE^{-/-}$  (n=6), IGF-1-infused  $L-Jak2^{+/+}ApoE^{-/-}$  (n=4), vehicle-infused  $L-Jak2^{-/-}ApoE^{-/-}$  (n=8) and IGF-1-infused  $L-Jak2^{-/-}ApoE^{-/-}$  (n=5) mice. Mice received insulin (0.75 units/kg) intraperitoneally and blood glucose was measured sequentially for 60 minutes. Data are expressed as a percentage of basal (fasting) glucose. **(C and D)** Total serum cholesterol and triglyceride from vehicle-infused  $L-Jak2^{+/+}ApoE^{-/-}$  (n=5), IGF-1-infused  $L-Jak2^{+/+}ApoE^{-/-}$  (n=3), vehicle-infused  $L-Jak2^{-/-}ApoE^{-/-}$  (n=3) and IGF-1-infused  $L-Jak2^{-/-}ApoE^{-/-}$  (n=4) mice. **(E)** Representative images of H&E and Oil-red-O (ORO) staining of liver sections from vehicle-infused  $L-Jak2^{-/-}ApoE^{-/-}$  (n=7,4) and IGF-1-infused  $L-Jak2^{-/-}ApoE^{-/-}$  (n=6,3) mice. Scale bars: 200  $\mu$ m (black), 300  $\mu$ m (grey). **(F)** Total hepatic triglyceride (TG) content in vehicle-infused  $L-Jak2^{-/-}ApoE^{-/-}$  (n=3) and IGF-1-infused  $L-Jak2^{-/-}ApoE^{-/-}$  (n=3) mice. Results are normalized to tissue weight. Each dot in the scatter plot indicates an individual animal. Data represent mean  $\pm$  SEM. Differences between groups were analyzed for statistical significance by Student unpaired t-test or One-way ANOVA with Newman-Keuls post-hoc test. \*P < 0.05; #P < 0.05 between  $L-Jak2^{+/+}ApoE^{-/-}$  + vehicle and  $L-Jak2^{-/-}ApoE^{-/-}$  + vehicle; //P < 0.05 between  $L-Jak2^{+/+}ApoE^{-/-}$  + IGF-1 and  $L-Jak2^{-/-}ApoE^{-/-}$  + IGF-1; ^P < 0.05 between  $L-Jak2^{+/+}ApoE^{-/-}$  + IGF-1 and  $L-Jak2^{-/-}ApoE^{-/-}$  + vehicle; +P < 0.05 between  $L-Jak2^{+/+}ApoE^{-/-}$  + vehicle and  $L-Jak2^{-/-}ApoE^{-/-}$  + IGF-1; \$P < 0.05 between  $L-Jak2^{-/-}ApoE^{-/-}$  + vehicle and  $L-Jak2^{-/-}ApoE^{-/-}$  + IGF-1.



**Supplemental Figure 4. Expression of *Igf1* transgene did not affect glucose tolerance or insulin sensitivity.** *L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>* and *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>* controls expressing an *Igf1* transgene in the liver (*L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>+</sup>* or *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>+</sup>*, respectively) and those not expressing the transgene (*L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>-</sup>* or *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>-</sup>*, respectively) were fed an atherogenic diet containing 0.2% cholesterol for 13-14 weeks, starting at 8 weeks of age. **(A)** Glucose tolerance test in overnight fasted *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>-</sup>* (n=4), *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>+</sup>* (n=8), *L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>-</sup>* (n=6) and *L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>+</sup>* (n=10) mice. Mice received glucose (1 g/kg) intraperitoneally and blood glucose was measured sequentially for 120 minutes. **(B)** Insulin tolerance test in 4 hour fasted *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>-</sup>* (n=4), *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>+</sup>* (n=8), *L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>-</sup>* (n=6) and *L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>+</sup>* (n=8) mice. Mice received insulin (0.75 units/kg) intraperitoneally and blood glucose was measured sequentially for 60 minutes. Data are expressed as a percentage of basal (fasting) glucose. Data represent mean  $\pm$  SEM. Differences between groups were analyzed for statistical significance by One-way ANOVA with Newman-Keuls post-hoc test. ^P < 0.05 between *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>+</sup>* and *L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>-</sup>*; #P < 0.05 between *L-Jak2<sup>+/+</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>-</sup>* and *L-Jak2<sup>-/-</sup>ApoE<sup>-/-</sup>Tg-Igf1<sup>-</sup>*.